within Pharmacolibrary.Drugs.ATC.N;

model N07XX04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.88,
    Cl             = 0.005833333333333333,
    adminDuration  = 600,
    adminMass      = 3.0,
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Sodium oxybate is the sodium salt of gamma-hydroxybutyric acid (GHB), a central nervous system depressant. It is primarily used for the treatment of narcolepsy with cataplexy and excessive daytime sleepiness. The drug is currently approved for medical use (notably under brand names such as Xyrem) in the United States, Europe, and other jurisdictions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers and patients with narcolepsy following oral administration.</p><h4>References</h4><ol><li>Melanie A Felmlee, Bridget L Morse, Marilyn E Morris,Î³-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.,The AAPS journal,2021<a href='https://pubmed.ncbi.nlm.nih.gov/33417072/'>https://pubmed.ncbi.nlm.nih.gov/33417072/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N07XX04;
